Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Carfilzomib
Drug ID BADD_D00367
Description Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.[L39392]
Indications and Usage Carfilzomib is indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval is based on response rate.
Marketing Status Prescription
ATC Code L01XG02
DrugBank ID DB08889
KEGG ID D08880
MeSH ID C524865
PubChem ID 11556711
TTD Drug ID D00UVA
NDC Product Code 50384-0180; 52076-6251; 76075-103; 50384-0230; 54893-0037; 76055-0035; 63552-009; 16436-0116; 63552-035; 50384-0260; 55111-985; 11722-059; 50384-0220; 50384-0210; 50384-0190; 67262-0010; 76075-102; 50384-0240; 42385-731; 76075-101
Synonyms carfilzomib | PR-171 | PR171 | Kyprolis
Chemical Information
Molecular Formula C40H57N5O7
CAS Registry Number 868540-17-4
SMILES CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3) NC(=O)CN4CCOCC4
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.003--
Acute myocardial infarction24.04.04.001; 02.02.02.001--Not Available
Acute pulmonary oedema22.01.03.005; 02.05.02.0040.001598%Not Available
Acute respiratory distress syndrome22.01.03.0010.000278%
Acute respiratory failure22.02.06.001; 14.01.04.0040.000208%Not Available
Ageusia17.02.07.001; 07.14.03.0030.001066%Not Available
Agitation19.06.02.001; 17.02.05.012--
Alanine aminotransferase increased13.03.01.003--
Alopecia23.02.02.001--
Ammonia increased13.03.01.0230.000533%Not Available
Amnesia19.20.01.001; 17.03.02.001--
Amyloidosis10.02.05.0010.000208%Not Available
Anaemia01.03.02.0010.011988%
Anaesthetic complication pulmonary22.02.07.005; 12.02.12.007--Not Available
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Angina pectoris02.02.02.002; 24.04.04.0020.001865%
Angioedema23.04.01.001; 10.01.05.009--Not Available
Anxiety19.06.02.002--
Aortic stenosis24.04.01.0010.000799%Not Available
Aortic valve incompetence02.07.03.0010.000533%Not Available
Aphasia19.21.01.001; 17.02.03.001--
Aphonia17.02.08.009; 22.02.05.024; 19.19.01.0020.000533%
Arrhythmia02.03.02.0010.002398%Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Arthropathy15.01.01.0030.001598%Not Available
Ascites07.07.01.001; 02.05.04.002; 09.01.05.003--
The 1th Page    1 2 3 4 5    Next   Last    Total 18 Pages